Abstract
GnRH agonist (GnRHa) medications are now routinely used by gynecologists, urologists, medical endocrinologists, and pediatric endocrinologists alike. GnRHa are frequently highly effective in diminishing pain derived from endometriotic lesions. Current US Food and Drug Administration approval limits GnRHa regimens to a 6-month course largely because of concern that the hypoestrogenic state invoked by the medication can lead to loss of bone mineral density. Most studies on this issue show either a very small diminution of bone density over this interval or no detectable changes. The role of GnRHa in shrinking uterine fibroids and/or diminishing bleeding, both before and during surgery is much more an adjunctive-to-definitive surgical intervention than a free-standing medical therapy. Attempts to suppress with GnRHa and co-administer estrogens with progestins or progestins alone, either concurrently or sequentially (delayed), are now being studied vigorously. The place of GnRHa in medical management of a variety of endocrine conditions is no the standard of care.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
